Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Biotechnology

Healthcare
$6.77 +1.96%

+$0.19 today

Market cap
$68.98M
Beta
0.11
P/E (TTM)
-14.7
EPS (TTM)
-$0.67
52W Low $3.92High $19.15

Volume 0.02M

Average 1.40M

ATRA Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Atara Biotherapeutics, Inc.NASDAQ: ATRA

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue declines year over year

Q1 FY2026 cost of revenue of $124K fell 99.4% year over year, behind the -97.7% change in trailing-twelve-month cost of revenue. Sequentially, it rose 19.2% from the prior quarter. Over 3 fiscal years it compounded at -57.2% a year.

Context

  • Cost of revenue amounted to 17.6% of revenue in FY2025, up 1.3 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -99.4% toward the trailing-twelve-month pace of -97.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$124K+19.2% QoQ
Last fiscal yearDec 2025
$21.21M+1.0% YoY
LTMMar 2026
$897K-97.7% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-99.4%——
1 year+1.0%——
3-year CAGR-57.2%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
21.21M USD
Year-over-year change
+1.0%
4-year CAGR
-47.6%

Cost of Revenue vs competitors

How ATRA compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -97.7% is the 7th highest of 9, against a peer median of -23.5%.
  • Cost of revenue amounts to 3.9% of revenue for ATRA, versus a peer median of 42.1%.
ATRA Competitors
Cost of Revenue for ATRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGNXMacroGenics, Inc.LTM Mar 2026$47.23M USD-18.4%+80.2%30.1%
CSBRChampions Oncology, Inc.LTM Jan 2026$31.36M USD+10.6%+6.3%54.1%
IFRXInflaRx N.V.LTM Mar 2026€7.26M EUR+133.7%—24746.3%
STTKShattuck Labs, Inc.LTM Mar 2026$1.82M USD-36.2%—182.0%
STROSutro Biopharma, Inc.LTM Mar 2026$1.28M USD-28.6%-4.0%1.3%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$897K USD-97.7%-57.2%3.9%
CLNNClene Inc.LTM Mar 2026$378K USD+410.8%+18.3%282.1%
CNTXContext Therapeutics Inc.LTM Mar 2026$40.17K USD———
OVIDOvid Therapeutics Inc.LTM Mar 2026$35K USD——0.5%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$31K USD-98.5%——
COYACoya Therapeutics, Inc.LTM Mar 2026$16.49K USD-99.9%-81.6%0.2%
Peer median (excluding ATRA) —-23.5%+6.3%42.1%

Competitors are the stored peer set for ATRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue20.34M63.57M8.57M128.94M120.77M
Cost of Revenue282M269.99M8.89M21.01M21.21M
Gross Profit(261.66M)(206.42M)(313K)107.93M99.56M
Gross Margin-1286.4%-324.7%-3.7%83.7%82.4%
Research & Development282M272.53M224.79M151.48M37.45M
Selling, General & Admin78.8M68.13M50.91M39.89M26.25M
Operating Expenses78.8M74.1M275.69M191.37M63.7M
Depreciation & Amortization9.35M5.65M4.83M5.05M2.12M
EBITDA(330.75M)(222.26M)(266M)(75.75M)38.63M
EBITDA Margin-1626.1%-349.6%-3102.7%-58.7%32.0%
Operating Income(340.46M)(280.51M)(276.01M)(83.44M)35.86M
Operating Margin-1673.9%-441.2%-3219.5%-64.7%29.7%
Interest Income367K3.06M5.43M2.11M683K
Interest Expense0373K5.29M4.62M3.79M
Other Income / Expenses367K52.22M(105K)(1.98M)(3.14M)
Income Before Tax(340.1M)(228.29M)(276.11M)(85.42M)32.72M
Pre-Tax Margin-1672.1%-359.1%-3220.7%-66.2%27.1%
Income Tax Expense46K12K15K(12K)31K
Net Income(340.14M)(228.3M)(276.13M)(85.4M)32.69M
Net Margin-1672.3%-359.1%-3220.9%-66.2%27.1%
EPS (Basic)(90.78)(55.96)(65.18)(11.41)2.61
EPS (Diluted)(90.78)(55.96)(65.18)(11.41)2.57
Weighted Avg Shares3.75M4.08M4.24M7.49M12.54M
Weighted Avg Shares (Diluted)3.75M4.08M4.24M7.49M12.72M

Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Intrinsic Alpha fair value

Locked

Current Price

$6.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.